Siri Tähtinen

2.1k total citations · 1 hit paper
32 papers, 1.6k citations indexed

About

Siri Tähtinen is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Siri Tähtinen has authored 32 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 22 papers in Genetics and 13 papers in Molecular Biology. Recurrent topics in Siri Tähtinen's work include CAR-T cell therapy research (26 papers), Virus-based gene therapy research (22 papers) and Immunotherapy and Immune Responses (11 papers). Siri Tähtinen is often cited by papers focused on CAR-T cell therapy research (26 papers), Virus-based gene therapy research (22 papers) and Immunotherapy and Immune Responses (11 papers). Siri Tähtinen collaborates with scholars based in Finland, United States and Germany. Siri Tähtinen's co-authors include Akseli Hemminki, Mikko Siurala, Anna Kanerva, Riikka Havunen, Suvi Sorsa, Markus Vähä‐Koskela, Vincenzo Cerullo, João M. Santos, Víctor Cervera-Carrascón and Susanna Grönberg-Vähä-Koskela and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Blood.

In The Last Decade

Siri Tähtinen

31 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines

2022 310 citations Siri Tähtinen, Ann-Jay Tong et al. Nature Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Siri Tähtinen Finland	20	1.0k	837	670	564	226	32	1.6k
Iulia Diaconu Finland	25	1.3k 1.3×	1.3k 1.5×	901 1.3×	504 0.9×	308 1.4×	37	2.0k
Łukasz Kuryk Poland	21	568 0.6×	641 0.8×	687 1.0×	302 0.5×	242 1.1×	61	1.4k
Dominic G. Roy Canada	18	644 0.6×	708 0.8×	466 0.7×	391 0.7×	164 0.7×	31	1.2k
Frederick J. Kohlhapp United States	14	1.3k 1.3×	1.1k 1.4×	919 1.4×	814 1.4×	260 1.2×	27	2.3k
Roshni Ravindranathan United States	12	805 0.8×	727 0.9×	337 0.5×	432 0.8×	157 0.7×	17	1.1k
Laura Evgin United States	16	639 0.6×	646 0.8×	378 0.6×	261 0.5×	121 0.5×	28	987
João M. Santos Finland	18	823 0.8×	691 0.8×	336 0.5×	366 0.6×	212 0.9×	39	1.1k
Marie‐Claude Bourgeois‐Daigneault Canada	18	1.0k 1.0×	542 0.6×	561 0.8×	1.0k 1.8×	109 0.5×	37	1.9k
Elizabeth J. Ilett United Kingdom	24	1.2k 1.2×	1.2k 1.5×	541 0.8×	602 1.1×	307 1.4×	38	1.9k
Kyle B. Stephenson Canada	20	767 0.8×	778 0.9×	385 0.6×	502 0.9×	121 0.5×	27	1.3k

Countries citing papers authored by Siri Tähtinen

Since Specialization

Citations

This map shows the geographic impact of Siri Tähtinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siri Tähtinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siri Tähtinen more than expected).

Fields of papers citing papers by Siri Tähtinen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siri Tähtinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siri Tähtinen. The network helps show where Siri Tähtinen may publish in the future.

Co-authorship network of co-authors of Siri Tähtinen

This figure shows the co-authorship network connecting the top 25 collaborators of Siri Tähtinen. A scholar is included among the top collaborators of Siri Tähtinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siri Tähtinen. Siri Tähtinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tong, Ann-Jay, Rebecca Leylek, Anna‐Maria Herzner, et al.. (2023). Nucleotide modifications enable rational design of TLR7-selective ligands by blocking RNase cleavage. The Journal of Experimental Medicine. 221(2). 12 indexed citations

Tähtinen, Siri, Ann-Jay Tong, Patricia Himmels, et al.. (2022). IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology. 23(4). 532–542. 310 indexed citations breakdown →

Liikanen, Ilkka, Dafne C.A. Quixabeira, Otto Hemminki, et al.. (2022). Oncolytic adenovirus decreases the proportion of TIM-3⁺ subset of tumor-infiltrating CD8⁺ T cells with correlation to improved survival in patients with cancer. Journal for ImmunoTherapy of Cancer. 10(2). e003490–e003490. 18 indexed citations

Tähtinen, Siri, Sara Feola, Cristian Capasso, et al.. (2020). Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Cancer Research. 80(12). 2575–2585. 40 indexed citations

Fusciello, Manlio, Flavia Fontana, Siri Tähtinen, et al.. (2019). Artificially cloaked viral nanovaccine for cancer immunotherapy. Nature Communications. 10(1). 5747–5747. 97 indexed citations

Cervera-Carrascón, Víctor, Mikko Siurala, João M. Santos, et al.. (2018). TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. OncoImmunology. 7(5). e1412902–e1412902. 90 indexed citations

Feola, Sara, Cristian Capasso, Manlio Fusciello, et al.. (2018). Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. OncoImmunology. 7(8). e1457596–e1457596. 40 indexed citations

Watanabe, Keisuke, Yanping Luo, Tong Da, et al.. (2018). Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 3(7). 215 indexed citations

Havunen, Riikka, João M. Santos, Suvi Sorsa, et al.. (2018). Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus. Molecular Therapy — Oncolytics. 11. 109–121. 45 indexed citations

10.

Hekim, Can, Mette Ilander, Jun Yan, et al.. (2017). Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunology Research. 5(2). 157–169. 37 indexed citations

11.

Havunen, Riikka, Mikko Siurala, Suvi Sorsa, et al.. (2017). Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. Molecular Therapy — Oncolytics. 4. 77–86. 103 indexed citations

12.

Liikanen, Ilkka, Siri Tähtinen, Kilian Guse, et al.. (2016). Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics. 15(9). 2259–2269. 30 indexed citations

13.

Siurala, Mikko, Riikka Havunen, Dipongkor Saha, et al.. (2016). Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Molecular Therapy. 24(8). 1435–1443. 43 indexed citations

14.

Watanabe, Keisuke, Sònia Guedan, John Scholler, et al.. (2016). Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells. Blood. 128(22). 3360–3360. 1 indexed citations

15.

Capasso, Cristian, Siri Tähtinen, Sara Carpi, et al.. (2016). Abstract A034: Boosting the efficacy of PD-L1 blockade with oncolytic vaccine for improved antitumor responses in melanoma. Cancer Immunology Research. 4(11_Supplement). A034–A034. 1 indexed citations

16.

Tähtinen, Siri, Susanna Grönberg-Vähä-Koskela, Mikko Siurala, et al.. (2015). Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunology Research. 3(8). 915–925. 59 indexed citations

17.

Tähtinen, Siri, Susanna Grönberg-Vähä-Koskela, Anna Kanerva, et al.. (2015). Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors. PLoS ONE. 10(6). e0131242–e0131242. 38 indexed citations

18.

Liikanen, Ilkka, Juuso Juhila, Riku Turkki, et al.. (2015). Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy. 24(1). 175–183. 25 indexed citations

19.

Kanerva, Anna, Petri Nokisalmi, Iulia Diaconu, et al.. (2013). Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research. 19(10). 2734–2744. 144 indexed citations

20.

Mattila, Elina, Niko Sahlberg, Pekka Kohonen, et al.. (2010). Inhibition of receptor tyrosine kinase signalling by small molecule agonist of T-cell protein tyrosine phosphatase. BMC Cancer. 10(1). 7–7. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact